Related Experiment Video
Updated: Aug 24, 2025
Analysis of Zebrafish Larvae Skeletal Muscle Integrity with Evans Blue Dye
Published on: November 30, 2015
Next-Generation SINE Compound KPT-8602 Ameliorates Dystrophic Pathology in Zebrafish and Mouse Models of DMD
Katherine G English1, Andrea L Reid1, Adrienne Samani1
1Department of Pediatrics, Division of Neurology at Children's of Alabama the University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Abstract:
Duchenne muscular dystrophy (DMD) is a progressive, X-linked childhood neuromuscular disorder that results from loss-of-function mutations in the DYSTROPHIN gene. DMD patients exhibit muscle necrosis, cardiomyopathy, respiratory failure, and loss of ambulation. One of the major driving forces of DMD disease pathology is chronic inflammation. The current DMD standard of care is corticosteroids; however, there are serious side effects with long-term use, thus identifying novel anti-inflammatory and anti-fibrotic treatments for DMD is of high priority. We investigated the next-generation SINE compound, KPT-8602 (eltanexor) as an oral therapeutic to alleviate dystrophic symptoms. We performed pre-clinical evaluation of the effects of KPT-8602 in DMD zebrafish (sapje) and mouse (D2-mdx) models. KPT-8602 improved dystrophic skeletal muscle pathologies, muscle architecture and integrity, and overall outcomes in both animal models. KPT-8602 treatment ameliorated DMD pathology in D2-mdx mice, with increased locomotor behavior and improved muscle histology. KPT-8602 altered the immunological profile of the dystrophic mice, and reduced circulating osteopontin serum levels. These findings demonstrate KPT-8602 as an effective therapeutic in DMD through by promotion of an anti-inflammatory environment and overall improvement of DMD pathological outcomes.
Insights
KPT-8602, a novel SINE compound, shows promise in treating Duchenne muscular dystrophy (DMD). This oral therapy improved muscle health and reduced inflammation in preclinical DMD models, offering a potential new treatment for this progressive neuromuscular disorder.
Area of Science:
- Neuromuscular Disorders
- Molecular Biology
- Pharmacology
Background:
- Duchenne muscular dystrophy (DMD) is a severe X-linked disorder caused by DYSTROPHIN gene mutations, leading to muscle degeneration and inflammation.
- Current corticosteroid treatments for DMD have significant long-term side effects, necessitating the search for novel therapies.
- Chronic inflammation is a key driver of DMD pathology, exacerbating muscle necrosis and fibrosis.
Purpose of the Study:
- To evaluate the therapeutic potential of KPT-8602 (eltanexor), a next-generation SINE compound, as an oral treatment for Duchenne muscular dystrophy.
- To assess the efficacy of KPT-8602 in ameliorating DMD symptoms and pathology in preclinical models.
Main Methods:
- Preclinical evaluation of KPT-8602 in Duchenne muscular dystrophy zebrafish (sapje) and mouse (D2-mdx) models.
- Assessment of muscle pathology, architecture, integrity, and locomotor behavior following KPT-8602 treatment.
- Analysis of immunological profiles and serum osteopontin levels in treated dystrophic mice.
Main Results:
- KPT-8602 significantly improved skeletal muscle pathologies, architecture, and integrity in both DMD zebrafish and mouse models.
- Treatment with KPT-8602 enhanced locomotor behavior and muscle histology in D2-mdx mice.
- KPT-8602 modulated the immunological profile in dystrophic mice and reduced circulating osteopontin levels.
Conclusions:
- KPT-8602 demonstrates significant therapeutic effects in preclinical models of Duchenne muscular dystrophy.
- The compound alleviates DMD pathology by promoting an anti-inflammatory environment and improving overall disease outcomes.
- KPT-8602 represents a promising novel oral therapeutic candidate for Duchenne muscular dystrophy.
